PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under Paperwork Reduction Act of 1995, no per	U.S. Patent ar Sons are required to respond to a collection o	nd Trademark Office; U.S. DEPARTMENT OF COM If information unless it displays a valid OMB control	number.
FILDELLIST	Application Number	10/642,248	
TRANSMITTAL	Filing Date	08/15/2003	
FORM	First Named Inventor	Paul L. DeAngelis	
	Art Unit	1656	
(to be used for all correspondence after initial filing)	Examiner Name	N. Nashed	
Total Number of Pages in This Submission	Attorney Docket Number	35542.097	
-			

Total	Number of	Pages in	This Submission					<u> </u>	J 4 2.031
FNCLOSURES (Chack all that apply)									
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation of POA, Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks 1. Transmittal Form (1 page); 2. Credit Card Payment Form (1 page); 3. Corrected Drawings (14 sheets); 4. Statement Accompanying Corrected Drawings (2 pages); 5. Copy of the Notice Regarding Drawings (2 pages); 6. Issue/Publication Fee Transmittal - PTOL-85B (in d. 7. Postcard.		After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
Firm Na Signatu		1/28/2			ODDING & ROGEF				
Sint de la company de la compa									
Date	Katnryn L. Hester, Ph.D.								
Date			01/16/2	UU/		Reg. No.	<u> </u>		46,768
CERTIFICATE OF TRANSMISSION/MAILING									
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: *** SENT BY EXPRESS MAIL NO. EV 767821673 US, DATED 01/16/2007*** Signature									
Typed o	or printed r	name	∣ '√Ka	athry	n L. Hester, Pl	n.D.		Date	01/16/2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL NO.: DATE DEPOSITED:

EV 767821673 US JANUARY 16, 2007 **PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

icant:

Paul L. DeAngelis

Atty Dkt No:

35542.097

Serial No:

10/642,248

Examiner:

N. Nashed

Filed:

August 15, 2003

Art Unit:

1656

Customer No.:

30589

Confirmation No.: 1560

For:

TARGETED GLYCOSAMINOGLYCAN POLYMERS BY POLYMER GRAFTING AND

METHODS OF MAKING AND USING SAME

Mail Stop - Issue Fee Commissioner for Patents Post Office Box 1450 Alexandria, Virginia 22313-1450

STATEMENT ACCOMPANYING CORRECTED DRAWINGS REQUIRED BY NOTICE OF ALLOWABILITY MAILED 11/14/2006

Applicant respectfully submits that the corrected drawings filed on September 5, 2006, which contained black and white photographs of electrophoresis gels, were acceptable drawings in compliance with 37 C.F.R. 1.121(d). These drawings clearly showed the features described in the Specification in varying shades of black, white and grey. However, when the Patent Office scanned in these drawings, no attention was paid to this detail, and the drawings present in the Image File Wrapper in PAIR contain solid black boxes rather than the black and white photographs. Applicants' representative would welcome the opportunity to send a faxed copy of these drawings upon request so the Office can be made aware of this problem.

However, to expedite issuance of a patent from the subject application, submitted herewith is a second set of corrected drawings. Such drawings have been further modified to provide a white or very light grey background with black electrophoresis bands. Applicants respectfully submit that these corrected drawings are in full compliance with 37 C.F.R. 1.121(d), and that such submission is a complete response to the Requirements of the Notice of Allowability mailed November 14, 2006.

Should the corrected drawings still be unacceptable to the Office, Applicants' representative respectfully requests she be immediately contacted at the number(s) below.

Respectfully submitted,

Kathryn L. Hester, Ph.D., Reg. No. 46,768

Customer No. 30589

Dunlap, Codding & Rogers, P.C.

Post Office Box 16370

Oklahoma City, Oklahoma 73113

(405) 607-8600 - Telephone

(405) 607-8686 - Telefax

Agent for Applicants

2	Application No.	Applicant(s)
JAN 1 6 cm 5	10/642,248	DEANGELIS ET AL.
JAN 1 6 2007 Sylotice of Allowability	Examiner	Art Unit
	Nashaat T. Nashed, Ph. D.	1656
The MAILING DATE of this communication appears clicking allowable, PROSECUTION ON THE MERITS IS derewith (or previously mailed), a Notice of Allowance (PTOL-85) AOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHT of the Office or upon petition by the applicant. See 37 CFR 1.313 This communication is responsive to 9/27/06.	(OR REMAINS) CLOSED in this or other appropriate communical IGHTS. This application is subject and MPEP 1308.	application. If not included tion will be mailed in due course. THIS ct to withdrawal from issue at the initiati
. X The allowed claim(s) is/are <u>1-10, 13,15-19,23-26,29-36,74</u>		
Acknowledgment is made of a claim for foreign priority unall All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which gives the complete of Draftspers (a) including changes required by the Notice of Draftspers (b) Corrected Draftspers (b) including changes required by the attached Examiner Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR deach sheet. Replacement sheet(s) should be labeled as such in the submin sheet. Replacement sheet(s) should be labeled as such in the subminimal priority with the subminimal priority and the subminimal priority with the subminimal priority and the subminimal priority with the subminimal priority and the subminimal priority with the su	e been received. e been received in Application Note been received in Application Note the attached EXAMIN res reason(s) why the oath or deceived the submitted. son's Patent Drawing Review (Parameter) is Amendment / Comment or in the drawing should be written on t	his national stage application from the ply complying with the requirements IER'S AMENDMENT or NOTICE OF claration is deficient. TO-948) attached The Office action of crawings in the front (not the back) of
DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	osit of BIOLOGICAL MATERIA	AL must be submitted. Note the
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	Paper No./Mail 7. ⊠ Examiner's Ame	nary (PTO-413), I Date

Application/Control Number: 10/642,248

Art Unit: 1656

The application has been amended as requested in the communication filed September 5, 2006 and September 27, 2006. Accordingly, claims 1-3, 6, 13, 15, 25, 77, 81, and 114 have been amended; new claim 115 has been added, and claims 11, 12, 20-22, 27-28, 37-73, 76, 79, 80, 82, 88-90, and 101-111 have been canceled.

The terminal disclaimer filed on September 5, 2006 disclaiming the terminal portion of any patent granted on this application, which would extend beyond the expiration date of U. S. patents 6,444,447 and 7,060,469 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Claims 1-10, 13, 15-19, 23-26, 29-36, 74, 75, 77, 78, 81, 83-87, 91-100, and 112-115 are pending and under consideration.

New corrected drawings in compliance with 37 CFR 1.121(d) are required in this application because Figures 20, 21, 26, 27, 28, 29, and 34 do not show the features described in the Figure description. In fact all of them can't be comprehended. The examiner recognizes the difficulties of obtaining good pictures for gels. A drawing of the gel showing the various bands of the gels would be acceptable with an amendment to the figure description indicating that the figure represents relative position of the different bands. Applicant is advised to employ the services of a competent patent draftsperson outside the Office, as the U.S. Patent and Trademark Office no longer prepares new drawings. The corrected drawings are required in reply to the Office action to avoid abandonment of the application. The requirement for corrected drawings will not be held in abeyance.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathryn L. Hester on October 16, 2006.

The application has been amended as follows:

In claim 1 (i) Line 5, delete "[,]"; and, (ii) in part (e), line two, delete ----[a]--- between "to" and "the".

Claim 4 The method of claim 1 wherein, in the step of providing at least one functional acceptor, the functional acceptor is a hyaluronic acid (HA) oligosaccharide having between about three sugar units and oligosaccharide polymer having molecular weight of about 4.2 kDa.

(attack	Application No.	Applicant(s)				
0"0 \$2						
JAN 1.6 2002 Betice of Allowability	10/642,248 Examiner	DEANGELIS ET AL. Art Unit				
JAN 1 6 2007						
	Nashaat T. Nashed, Ph. D.	1656				
All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course. THIS				
1. This communication is responsive to <u>9/27/06</u> .						
2. The allowed claim(s) is/are <u>1-10, 13,15-19,23-26,29-36,74</u>		<u>112-115</u> .				
3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the:						
 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 						
Copies of the certified copies of the priority do-						
International Bureau (PCT Rule 17.2(a)).		Nanchard Springer				
* Certified copies not received:						
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be subm	MENT of this application. itted. Note the attached EXAMINER	S'S AMENDMENT or NOTICE OF				
INFORMAL PATENT APPLICATION (PTO-152) which give		ation is deficient.				
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.						
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date						
(b) ⊠ including changes required by the attached Examiner's Amendment / Comment or in the Office action of						
Paper No./Mail Date						
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).						
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Informal I	Patent Application				
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	y (PTO-413),				
Paper No./Mail Date 3.						
Paper No./Mail Date 4.	8. 🗌 Examiner's Statem	ent of Reasons for Allowance				
of Biological Material 9. Other						
1						

Application/Control Number: 10/642,248

Art Unit: 1656

The application has been amended as requested in the communication filed September 5, 2006 and September 27, 2006. Accordingly, claims 1-3, 6, 13, 15, 25, 77, 81, and 114 have been amended; new claim 115 has been added, and claims 11, 12, 20-22, 27-28, 37-73, 76, 79, 80, 82, 88-90, and 101-111 have been canceled.

The terminal disclaimer filed on September 5, 2006 disclaiming the terminal portion of any patent granted on this application, which would extend beyond the expiration date of U. S. patents 6,444,447 and 7,060,469 has been reviewed and is accepted. The terminal disclaimer has been recorded.

Claims 1-10, 13, 15-19, 23-26, 29-36, 74, 75, 77, 78, 81, 83-87, 91-100, and 112-115 are pending and under consideration.

New corrected drawings in compliance with 37 CFR 1.121(d) are required in this application because Figures 20, 21, 26, 27, 28, 29, and 34 do not show the features described in the Figure description. In fact all of them can't be comprehended. The examiner recognizes the difficulties of obtaining good pictures for gels. A drawing of the gel showing the various bands of the gels would be acceptable with an amendment to the figure description indicating that the figure represents relative position of the different bands. Applicant is advised to employ the services of a competent patent draftsperson outside the Office, as the U.S. Patent and Trademark Office no longer prepares new drawings. The corrected drawings are required in reply to the Office action to avoid abandonment of the application. The requirement for corrected drawings will not be held in abeyance.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathryn L. Hester on October 16, 2006.

The application has been amended as follows:

In claim 1 (i) Line 5, delete "[,]"; and, (ii) in part (e), line two, delete ----[a]--- between "to" and "the".

Claim 4 The method of claim 1 wherein, in the step of providing at least one functional acceptor, the functional acceptor is a hyaluronic acid (HA) oligosaccharide having between about three sugar units and oligosaccharide polymer having molecular weight of about 4.2 kDa.